Indonesia is in talks with Russia to enhance its domestic pharmaceutical production by exploring technology transfer opportunities. The discussions, aimed at reducing dependency on imports and improving regulatory oversight, were held between Indonesia’s Food and Drug Authority (BPOM), led by Taruna Ikrar, and Russian Deputy Minister of Industry and Trade, Alexey Vladimirovich Gruzdev.
The focus of these discussions was on bolstering local production capabilities, particularly for essential medicines like diabetes treatments, including insulin and glucagon-like peptide-1 (GLP-1) medicines. Other areas identified for potential collaboration include cancer treatments, monoclonal antibodies, antiviral medicines, and advanced biotechnology products.
Russian pharmaceutical companies have shown interest in transferring technology and establishing manufacturing facilities in Indonesia, with a keen focus on insulin, oncology medicines, and biotechnology products. Several Russian firms have already submitted product registration documents to BPOM, indicating a commitment to this partnership.
The dialogue also covered existing partnerships in Good Manufacturing Practice (GMP) inspections, technical training, and information sharing. Both countries are working towards finalizing a memorandum of understanding to establish a framework for deeper collaboration. Russia proposed the idea of mutual recognition of GMP certificates to simplify regulatory processes and facilitate market access, which will require further discussion to ensure regulatory compatibility.
In an effort to enhance Indonesia’s inspection capabilities, Russia offered technical training that includes virtual reality-based simulations to prepare inspectors for pharmaceutical manufacturing assessments. Additionally, the discussions included digital regulatory systems and supply-chain monitoring, with both sides expressing interest in continuing negotiations and expanding cooperation through further meetings and visits to pharmaceutical manufacturing facilities.